Zocilurtatug (Synonyms: ZL-1310 Antibody) |
Catalog No.GC81456
One-Click Copy Product Info
|
Zocilurtatug (ZL-1310 Antibody) is a human monoclonal antibody targeting DLL3.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 3058592-86-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
In Vitro, Antibody-drug conjugates (ADCs) are a novel class of anti-tumor drugs, consisting of three parts: a targeting antibody—which specifically recognizes tumor cell surface antigens and acts as a "navigator"; a linker; and a cytotoxic payload. Zocilurtatug can serve as the targeting antibody component of an ADC, conjugated with a topoisomerase I inhibitor (camptothecin derivative) payload via a cleavable linker to form the complete ADC Zocilurtatug pelitecan. This allows for precise delivery of the cytotoxic payload to DLL3-positive tumor cells, killing tumor cells while minimizing damage to normal cells[1][2].
References:
[1]. American Association for Cancer Research (AACR). Investigational Antibody-drug Conjugate Shows Clinical Benefit Against Previously Treated Small Cell Lung Cancer. News Release. October 22, 2025.
[2]. Kemper M, et al. Redefining the Fight Against SCLC: Standards, Innovations, and New Horizons. Cancers (Basel). 2025 Jul 7;17(13):2256.
| Cas No. | 3058592-86-9 | SDF | |
| Synonyms | ZL-1310 Antibody | ||
| Formula | M.Wt | 145.55 | |
| Solubility | Storage | Store at -20°C | |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 6.8705 mL | 34.3525 mL | 68.7049 mL |
| 5 mM | 1.3741 mL | 6.8705 mL | 13.741 mL |
| 10 mM | 687 μL | 3.4352 mL | 6.8705 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A liquid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)